title: Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia.
abstract: To overcome the drug resistance phenomenon induced by Imatibib (IM), in clinical practice, are often used second generation of tyrosine kinase inhibitors as Nilotinib (NIL); a such potent inhibitor of the BCR/ABL kinase and Dasatinib (DAS), a inhibitor of BCR/ABL kinase, and inhibitor SrC family kinase. In this study we evaluated the in vivo effect of DAS, NIL, and IM on intracellular calcium concentration, oxidative stress, and apoptosis in peripheral blood leukocytes of 45 newly diagnosed patients with chronic myeloid leukaemia (CML-PBM). Our data demonstrated that treatment with DAS and NIL showed an higher modulating potential than IM on intracellular calcium concentration by inhibiting the thapsigargin, a sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor, and Lithium (Li) an inositol 1,4,5-triphosphate (InsP3) receptor inhibitor activities. Moreover our data demonstrated that NIL and DAS have significantly increased apoptosis more than IM by involving both intracellular calcium signaling as well as oxidative stress. The acquisition of the oxidative stress and calcium channels receptors values data could help the hematologist to modulate and improve the treatment of chronic myeloid leukaemia (CML) pathology.
authors.affiliation: Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", Naples, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Ciarcia
authors.affiliation: Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", Naples, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Damiano
authors.affiliation: Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", Naples, Italy.
authors.forename: Maria Valeria
authors.initials: MV
authors.lastname: Puzio
authors.affiliation: Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", Naples, Italy.
authors.forename: Serena
authors.initials: S
authors.lastname: Montagnaro
authors.affiliation: Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", Naples, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Pagnini
authors.affiliation: Clinical Trials Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G. Pascale-IRCCS, Naples, Italy.
authors.forename: Carmen
authors.initials: C
authors.lastname: Pacilio
authors.affiliation: Department of Haematology, ASL Caserta (CE), Hospital Moscati, Aversa (CE), Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Caparrotti
authors.affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
authors.forename: Cristiana
authors.initials: C
authors.lastname: Bellan
authors.affiliation: AORN Dei Colli Monaldi UOC, Oncology, Naples, Italy.
authors.forename: Tiziana
authors.initials: T
authors.lastname: Garofano
authors.affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
authors.forename: Maria Sole
authors.initials: MS
authors.lastname: Polito
authors.affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.|AORN Dei Colli Monaldi UOC, Oncology, Naples, Italy.|Sbarro Institute for Cancer Research and Molecular Medicine, Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania.
authors.forename: Antonio
authors.initials: A
authors.lastname: Giordano
authors.affiliation: Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", Naples, Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Florio
mesh_terms: D000328:Adult; D000069439:Dasatinib / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib